TRPV1 and Alzheimer disease: In the subsequent phase III trial, it achieved a 44.3% mean improvement in EASI and a 36.0% IGA 0/1 response rate, indicating both antipruritic and anti-inflammatory efficacy compared to placebo (166).In parallel, traditional herbal formulations such as Zhenxin Anshen formula have been shown in both AD mouse models and in vitro systems to suppress TRPV1 and TRPA1 expression, reduce scratching behavior, and downregulate inflammatory mediators including IgE, IL-4, IL-5, IL-13, and TSLP.